85 related articles for article (PubMed ID: 3811070)
21. [Blastomogenic activity of 3-hydroxyanthranilic acid in dogs].
Khrustalev SA; Khar'kovskaia NA
Vopr Onkol; 1980; 26(3):93-6. PubMed ID: 7368666
[No Abstract] [Full Text] [Related]
22. Recognition of "early" bladder cancer and premalignant epithelial changes.
Friedell GH
Cancer Res; 1977 Aug; 37(8 Pt 2):2792-3. PubMed ID: 872105
[No Abstract] [Full Text] [Related]
23. [Tryptophan metabolic disorder--1 of the criteria for forming groups at high risk for spontaneous bladder cancer].
Prianichnikova MB
Urol Nefrol (Mosk); 1984; (4):61-5. PubMed ID: 6236595
[No Abstract] [Full Text] [Related]
24. Increased levels of serum lipofuscin derived from 3-hydroxyanthranilic acid in patients with chronic renal failure.
Hegedus ZL; Frank HA; Steinman TI; Altschule MD; Nayak U
Arch Int Physiol Biochim; 1987 Dec; 95(5):457-63. PubMed ID: 2452619
[TBL] [Abstract][Full Text] [Related]
25. Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer.
Koçak H; Oner-Iyidoğan Y; Koçak T; Oner P
Clin Biochem; 2004 Aug; 37(8):673-8. PubMed ID: 15302609
[TBL] [Abstract][Full Text] [Related]
26. Flat intraepithelial lesions of the urinary bladder.
Cheng L; Cheville JC; Neumann RM; Bostwick DG
Cancer; 2000 Feb; 88(3):625-31. PubMed ID: 10649257
[TBL] [Abstract][Full Text] [Related]
27. [Detection of an antigen containing 3-hydroxyanthranilic acid in the sera of patients with tumors of different localizations].
Korosteleva TA; Kliucharev BV; Mel'nikov RA; Belokhvostova AT
Biull Eksp Biol Med; 1976 Jul; 82(7):850-2. PubMed ID: 953351
[TBL] [Abstract][Full Text] [Related]
28. [Cystic cystitis--a precancerous condition?].
Türk C; Marberger M; Kosak D
Helv Chir Acta; 1982 Aug; 49(3-4):401-4. PubMed ID: 7129908
[No Abstract] [Full Text] [Related]
29. Coincidence of bladder and prostate cancer.
Chun TY
J Urol; 1997 Jan; 157(1):65-7. PubMed ID: 8976217
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.
Nagao K; Itoh Y; Fujita K; Fujime M
Int J Urol; 2007 Sep; 14(9):795-9. PubMed ID: 17760744
[TBL] [Abstract][Full Text] [Related]
31. [Ultrasonic scanning in determining the local spread of bladder cancer].
Tsyb AF; Slesarev VI; Grishin GN; Kariakin OB; Dunchik VN
Med Radiol (Mosk); 1985 Oct; 30(10):39-44. PubMed ID: 3903420
[TBL] [Abstract][Full Text] [Related]
32. [Clinical and diagnostic characteristics of the early forms of stomach cancer].
Sokolov LK; Zakharov PI; Golubeva SV; Barchunov BN; Siniaev VP
Ter Arkh; 1986; 58(1):74-7. PubMed ID: 3961696
[TBL] [Abstract][Full Text] [Related]
33. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up.
Corica FA; Husmann DA; Churchill BM; Young RH; Pacelli A; Lopez-Beltran A; Bostwick DG
Urology; 1997 Sep; 50(3):427-31. PubMed ID: 9301710
[TBL] [Abstract][Full Text] [Related]
34. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
35. Absorption of 14 C-labeled 3-hydroxy-L-kynurenine and 3-hydroxyanthranilic acid from the mouse urinary bladder under carcinogenic conditions.
Bryan GT; Morris CR; Brown RR
Cancer Res; 1965 Oct; 25(9):1432-7. PubMed ID: 5861071
[No Abstract] [Full Text] [Related]
36. [Clinical evaluation of urinary basic fetoprotein and the BTA test for detection of bladder cancer].
Imamura M; Inoue K; Megumi Y; Nishimura M; Ohmori K; Nishimura K
Hinyokika Kiyo; 2000 Oct; 46(10):705-9. PubMed ID: 11215195
[TBL] [Abstract][Full Text] [Related]
37. Urinary excretion of 3-hydroxyanthranilic acid in neoplastic diseases and its biological effects.
Quagliariello E; Alifano A; Papa S
Acta Vitaminol; 1965 Dec; 19(5):169-78. PubMed ID: 5899056
[No Abstract] [Full Text] [Related]
38. Diagnostic delay and prognosis in invasive bladder cancer.
Liedberg F; Anderson H; Månsson A; Månsson W
Scand J Urol Nephrol; 2003; 37(5):396-400. PubMed ID: 14594688
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.
Sánchez-Carbayo M; Urrutia M; González de Buitrago JM; Navajo JA
Clin Cancer Res; 2000 Sep; 6(9):3585-94. PubMed ID: 10999749
[TBL] [Abstract][Full Text] [Related]
40. [Serum 3-hydroxyanthranilic acid determination in the early stages of experimental carcinogenesis].
Korosteleva TA; Zasypka AT
Vopr Onkol; 1970; 16(10):47-50. PubMed ID: 4995976
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
